>> 1871> Reporter> Dr. Zhengyi Wang, Vice President of Tianjing Bio-Drug Discovery
Jianfan Bio: Obtained the medical device registration certificate for disposable hemodialysis tubing
Time of Update: 2021-07-18
On March 15th, Jianfan Biological announced that the company has recently received the "Medical Device Registration Certificate" issued by the National Medical Products Administration.
Covestro: New bio-based curing agent succeeds in water-based coatings
Time of Update: 2021-07-15
Global Coatings Network News:Global Coatings Network News: Global Coatings Network News: Furniture manufacturers are constantly striving to achieve more sustainable production and reduce carbon footprint.
Tianjing Bio will hold 2021 Investor R&D Day
Time of Update: 2021-07-14
It is committed to the target biological research of innovative biopharmaceuticals, antibody technology, and clinical development and product commercialization in China and the United States.
Zhu Jielun, and Chief Commercial Officer Mr.
Tianjing Bio and ABL Bio announce that TJ-CD4B/ABL111 has been approved by the FDA for Phase 1 clinical trials
Time of Update: 2021-07-13
, We will continue to work with Tianjing Bio to accelerate the progress of clinical research and development, and strive to bring new treatment options to patients with advanced and metastatic solid tumors as soon as possible .
Tianjing Bio and ABL Bio announce the completion of the first patient administration of TJ-L14B Phase 1 U.S. clinical study
Time of Update: 2021-07-11
Tolcher, the chief investigator of this phase 1 clinical study, CEO and Director of the Clinical Research Center of NEXT Oncology, said: "TJ-L14B/ABL503 has demonstrated the potential for safety and anti-tumor activity.
Connoa Bio submitted the IPO prospectus of the Hong Kong Stock Exchange
Time of Update: 2021-07-11
The prospectus disclosed that Connoa's drug discovery and development work was jointly led by Chairman of the Board and Chief Executive Officer Chen Bo and Senior Vice President Wang Changyu .
Junshi Bio-Treprimumab injection is approved for the treatment of urothelial cancer
Time of Update: 2021-07-11
On February 19th, the second indication of teriprizumab injection was approved for the treatment of recurrent/metastatic nasopharyngeal carcinoma (NPC) that had previously failed second-line and above systemic treatments .
Genxi Bio announced the completion of the first patient enrollment in the Phase I/II registered
Time of Update: 2021-07-11
The phase I/II registered clinical study of the donor-derived allogeneic, anti-CD19 chimeric antigen receptor (CAR)-T cell therapy GC007g for cell leukemia (B-ALL) completed the first patient enrollment .
Kangtai Bio-New Coronary Inactivated Vaccine Data: Neutralizing Antibody Is 2.65 Times Recovered
Time of Update: 2021-07-10
The clinical data of the new crown vaccine compiled by the medical team of Dongxing Securities shows that the antibody titer vaccine group/recovered multiple of them ranks first in China and fourth in the world .
Bluebird Bio launches Zynteglo in Europe blocked and starts layoffs
Time of Update: 2021-07-08
Due to the frustration of Zynteglo's listing on the first European market, Bluebird Bio is currently laying off employees and plans to "reduce and reshape" its workforce in parts of Germany .
Junshi Bio-Treplimumab first-line treatment of esophageal cancer phase III clinical trial reached the primary endpoint
Time of Update: 2021-07-08
Junshi Biotech announced that the company’s self-developed anti-PD-1 monoclonal antibody drug teriprizumab combined with chemotherapy for the first-line treatment of advanced esophageal squamous cell carcinoma is a randomized, double-blind, placebo-controlled, multi-center phase III clinical study (JUPITER).
Yu Xuefeng, Chairman of CanSino Bio: Compared with the new crown vaccine production capacity, I want to raise the issue of production efficiency more
Time of Update: 2021-07-08
How do you view the status of the domestic new crown vaccine supply, production capacity and raw materials?
